Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naive patients with Crohn's Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study

Di Giuseppe R, Plachta-Danielzik S, Bokemeyer B, Efken P, Mohl W, Hoffstadt M, Krause T, Schweitzer A, Schnoy E, Atreya R, Teich N, Trentmann L, Ehehalt R, Franzenburg S, Hartmann P, Schreiber S (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Journal of Crohns & Colitis Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: I120-I121

Conference Proceedings Title: JOURNAL OF CROHNS & COLITIS

DOI: 10.1093/ecco-jcc/jjab232.116

Authors with CRIS profile

Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur)

Involved external institutions

Kompetenznetz Darmerkrankungen e.V. DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) Universitätsklinikum Augsburg DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Interdisziplinäres Crohn Colitis Centrum Rhein-Main - iCCC DE Germany (DE)

How to cite

APA:

Di Giuseppe, R., Plachta-Danielzik, S., Bokemeyer, B., Efken, P., Mohl, W., Hoffstadt, M.,... Schreiber, S. (2022). Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naive patients with Crohn's Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study. In JOURNAL OF CROHNS & COLITIS (pp. I120-I121). OXFORD: OXFORD UNIV PRESS.

MLA:

Di Giuseppe, R., et al. "Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naive patients with Crohn's Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study." Proceedings of the JOURNAL OF CROHNS & COLITIS OXFORD: OXFORD UNIV PRESS, 2022. I120-I121.

BibTeX: Download